Overview

Irinotecan and Temozolomide for Ewing Sarcoma

Status:
Recruiting

Trial end date:
2025-02-28

Target enrollment:

Participant gender:

Summary

The investigators explored the activity of vincristine and irinotecan combined with temozolomide (VIT) in patients with relapsed and metastatic Ewing Sarcoma.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Treatments:

Camptothecin
Dacarbazine
Irinotecan
Temozolomide
Vincristine